Has Claudia Espinosa received payments from drug or device companies?

Yes. Drug and device makers reported $75,278 in general payments to Claudia Espinosa across 102 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Claudia Espinosa did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Claudia Espinosa come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Claudia Espinosa

Pediatric Infectious Diseases · Tampa, FLNPI 1093840522

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (51.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Sanofi Pasteur Inc. at 52.2% of the total. 2025 is the largest year on record at $18,851, 2.8 times the $6,622 reported in 2019. Among pediatric infectious diseases clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$75,278in general payments, 2019–2025

Across 102 payments — averaging $738.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi Pasteur Inc.$39K
Astellas Pharma US Inc$22K
Gilead$11K
Janssen Scientific Affairs, LLC$2K
Merck$677
Sobi, Inc$216
plus $95 from 1 others

$708,435in research payments, 2019–2025

Across 93 payments — averaging $7617.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Merck$360K
AstraZeneca$177K
Melinta Therapeutics, LLC$68K
Janssen Research & Development, LLC$48K
AbbVie$39K
Gilead$16K

What the payments were for

Consulting fees$39,03052%
Speaking & faculty fees$24,46532%
Travel & lodging$8,73812%
Food & beverage$2,7194%
Education$3250%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi Pasteur Inc.	55	$39,260
Astellas Pharma US Inc	33	$22,188
Gilead	4	$10,822
Janssen Scientific Affairs, LLC	1	$2,020
Merck	6	$677
Sobi, Inc	2	$216
AbbVie	1	$95

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$75,278 in reported general payments places this provider in the 95th percentile of 41 pediatric infectious diseases providers in Florida.

See all pediatric infectious diseases providers in Florida →

Other pediatric infectious diseases in Tampa

Carina RodriguezTampa$2K
Lisa SandersTampa$347
David BermanSt Petersburg$48K
Mobeen RathoreJacksonville$33K
Ana AlvarezJacksonville$4K
Gwendolyn ScottMiami$3K
Pablo LauferMiami$2K
Ivan GonzalezMiami$2K
Manuel CotillaMiami$2K
Robert ReidHollywood$1K

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →